Drugs / Imvotamab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06524687 | May 2024 → Jan 2025 | idiopathic inflammatory myopathy | IGM Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06041568 | Aug 2023 → Jan 2025 | systemic lupus erythematosus | IGM Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06087406 | Mar 2023 → Feb 2025 | rheumatoid arthritis | IGM Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04082936 | Sep 2019 → Feb 2024 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | IGM Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT06331832 | — | non-Hodgkin lymphoma | IGM Biosciences, Inc. | No longer available | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imvotamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087406 ↗ |
| Known as | IGM-2323 | “A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With...” NCT04082936 ↗ |
| Action | Deplete | “Imvotamab is able to eliminate CD20-positive lymphoma cells by engaging T-cells and lymphoma cells, leading to T-cell dependent cellular cytotoxicity.” NCT04082936 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594476 ↗ |
| Route | Intravenous | “imvotamab will be administered intravenously (IV).” NCT04082936 ↗ |